VRNA:NSD-Verona Pharma PLC ADR (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 75.06

Change

0.00 (0.00)%

Market Cap

USD 6.06B

Volume

0.86M

Analyst Target

USD 18.40
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 65.38B
ARGX argenx NV ADR

N/A

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 32.75B
ONC BeiGene, Ltd.

N/A

USD 27.70B
SMMT Summit Therapeutics PLC

N/A

USD 27.07B
RPRX Royalty Pharma Plc

N/A

USD 18.40B
INSM Insmed Inc

N/A

USD 11.84B
INCY Incyte Corporation

N/A

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 11.29B

ETFs Containing VRNA

SBIO ALPS Medical Breakthrough.. 5.34 % 0.50 %

N/A

USD 0.08B
AADR AdvisorShares Dorsey Wrig.. 4.82 % 0.00 %

N/A

USD 0.05B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 61.63% 95% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 61.63% 95% A 95% A
Trailing 12 Months  
Capital Gain 523.42% 99% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 523.42% 99% N/A 99% N/A
Trailing 5 Years  
Capital Gain 1,666.12% 99% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,666.12% 99% N/A 99% N/A
Average Annual (5 Year Horizon)  
Capital Gain 96.05% 85% B 93% A
Dividend Return 96.05% 85% B 93% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 143.18% 29% F 14% F
Risk Adjusted Return 67.08% 98% N/A 88% B+
Market Capitalization 6.06B 96% N/A 90% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector